Akero Therapeutics, Inc.

Carmot Therapeutics, Inc. is a biopharmaceutical company headquartered in Berkeley, California, focused on discovering and developing innovative treatments for metabolic diseases and obesity.

89bioBiotechIsrael

72% match

89bio is a clinical-stage biopharmaceutical company that develops innovative therapies for patients with liver and cardiometabolic diseases. The company utilizes its expertise in FGF21 as a master metabolic regulator to create treatments, such as pegozafermin, for conditions with limited or no approved therapeutic options.

Metacrine, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California. The company builds a pipeline of differentiated therapies targeted at treating liver and gastrointestinal diseases.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.

Marea Therapeutics, Inc.BiotechnologyUnited States

71% match

Marea Therapeutics is a biotechnology research company headquartered in South San Francisco, California. The company focuses on developing novel therapeutics within the biopharma sector.

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to developing innovative therapies for metabolic and endocrine disorders. Its flagship product candidate, VK2809, is an orally administered, tissue- and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß). Currently, VK2809 is undergoing Phase IIb clinical trials to address non-alcoholic steatohepatitis (NASH) confirmed by biopsy, as well as non-alcoholic fatty liver disease (NAFLD). The company's pipeline further features VK5211, an orally available non-steroidal selective androgen receptor modulator, which is in Phase II trials for patients convalescing from non-elective hip fracture surgery. Additionally, VK0612, an oral candidate poised for Phase IIb evaluation, targets type 2 diabetes. Lastly, VK0214, another orally administered TRß selective agonist, is being developed for X-linked adrenoleukodystrophy. Established in 2012, Viking Therapeutics maintains its corporate headquarters in San Diego, California.